Detalles de la búsqueda
1.
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
Blood
; 140(1): 45-57, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35452517
2.
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
Cancer Sci
; 112(8): 3029-3040, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34058788
3.
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy.
Haematologica
; 106(7): 1857-1866, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499243
4.
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
J Immunol
; 198(4): 1585-1594, 2017 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28062698
5.
CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
N Engl J Med
; 380(5): 496-7, 2019 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30702240
6.
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.
J Immunol
; 195(10): 5077-87, 2015 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26475927
7.
Antibody Isotypes for Tumor Immunotherapy.
Transfus Med Hemother
; 44(5): 320-326, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29070977
8.
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
Transfus Med Hemother
; 44(5): 292-300, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29070974
9.
Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.
J Immunol
; 193(3): 1485-95, 2014 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24973443
10.
Complement in antibody-based tumor therapy.
Crit Rev Immunol
; 34(3): 199-214, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24941073
11.
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Br J Haematol
; 181(3): 413-417, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449349
12.
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.
Front Immunol
; 13: 949140, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36052078
13.
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Front Immunol
; 13: 929339, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36389667
14.
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.
Front Immunol
; 13: 957874, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36119088
15.
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Blood Adv
; 6(16): 4847-4858, 2022 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35820018
16.
Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo.
J Clin Med
; 10(12)2021 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34203833
17.
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20.
Blood Adv
; 5(19): 3807-3820, 2021 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34525171
18.
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
J Clin Invest
; 131(6)2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33561014
19.
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.
Front Immunol
; 11: 560244, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33324393
20.
Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.
Mol Immunol
; 124: 200-210, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32599335